Transforming veterinary health with AI-powered biotech solutions
Organised Recombinant Protein Complex Platform OrigamiVax
Inspired by the elegant Japanese origami arts, we strive to combine de novo sequence design and protein engineering technologies to develop better vaccines.
- Correct and stabilised structure to induce neutralising/protective antibodies
- Extra T cell help through engineering of epitopes from pathogen’s genome
- Organised higher order complexes to boost immunogenicity and maintain thermo stability
- Avoid using vectors, carriers, multimerisation domains of other pathogens to minimise unwanted immune responses.
Next Generation Nucleic Acids Based Vaccines
Depending on the immune responses required, nucleic acid based vaccines can be quickly developed, validated and manufactured to combat emerging diseases.
- Taking advantage of LLM to generate nucleic sequences for better expression.
- Self circularising mRNA technology (SeCuRNA) to increase stability and potency.
- Incorporate molecular adjuvants to boost immunogenicity.
- Highly efficient polymer based delivery system.
Next Generation Adjuvant Discovery for Veterinary Use
With high throughput in silico docking and screening, plus dedicated reporter cells, we search for safe and potent vaccine adjuvants and immune modulators specific for different animals. Particularly, we’re interested to screen and develop good mucosal adjuvants as sIgA induced through mucosal immunity is the first layer protection against different pathogens entering through mucosal surfaces.
- Taking advantage of high performance computing.
- High throughput validation on dedicated reporter cells for fast discovery.
- Tailored adjuvants discovery to match with particular vaccine and animal type.
- AI/ML to train and optimise prediction models to expedite the discovery process.
- Discover safe and potent mucosal adjuvants to induce high sIgA.